NCT04925661 - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

August 29, 2023

Study Completion Date

August 29, 2023

Conditions

Chronic Kidney DiseasesRenal Anemia

Interventions

DRUG

HEC53856

Either dose of HEC53856 will be administered after fasting .

DRUG

Roxadustat

Roxadustat will be administered after fasting .

DRUG

Placebo

Either dose of placebo will be administered after fasting .

Trial Locations (8)

The sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

Zhejiang Provincal People's Hospital, Hangzhou

The People's Hospital of Guangxi Zhuang Autonmous Region, Nanning

Huashan Hospital, Shanghai

Ruijin Hospital, Shanghai

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors

collaborator

Nicoya Therapeutics (Shanghai) Co., Ltd.

UNKNOWN

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY